Objective: Understand when and why antibody combinations exhibit synergy

Methods

- There are four classes of SARS-CoV-2 antibodies based on binding behavior and location on the receptor binding domain (RBD).
- This study tested S309 (a Class 3 antibody) as well as five other antibodies alone and in combination with S309.
- PyMOL protein modeling was used to visualize binding to the SARS-CoV-2 RBD, and antibodies that did not exhibit overlap with S309 were selected.
- Antibodies were tested against the D614G variant, an original SARS-CoV-2 variant, and the BA.2.75 variant, a variant that first emerged in 2022.

Results

### Class 4 + S309
- S309 + 10-40 (D614G)
- S309 + 10-40 (BA.2.75)

### Class 1 + S309
- S309 + Omi-3 (D614G)
- S309 + Omi-3 (BA.2.75)
- S309 + Omi-18 (D614G)
- S309 + Omi-18 (BA.2.75)

### Class 2 + S309
- S309 + XGV347 (D614G)
- S309 + XGV347 (BA.2.75)
- S309 + ZCB11 (D614G)
- S309 + ZCB11 (BA.2.75)

Discussion

**Synergy** was only observed when **Class 2** antibodies in combination with S309 were tested against the **BA.2.75** variant.

### Variant
- The BA.2.75 variant undergoes a conformational change upon S309 binding (Cao et al., 2022).
- This change could make it easier for the antibody in combination with S309 to bind to the RBD.

### Class
- Class 1: Binds to “up” RBDs
- Class 2: Binds to “up” and “down” RBDs
- Class 4: Binds to “up” RBDs
- S309 (Class 3): Binds to “down” RBDs

(Barnes et al., 2020; Pinto et al., 2020)

- Therefore, only Class 2 antibodies can bind to the same RBD conformation as S309 and benefit from synergistic interactions.

**All images displayed were created by Jacob Gross**